GSK Update On FDA Review Of Promacta(R) (Eltrombopag) (Medical News Today)
GlaxoSmithKline (NYSE: GSK) announced that the United States Food and Drug Administration has extended the priority review period for PROMACTA(R) (eltrombopag) for the short-term treatment of previously treated patients with chronic idiopathic thrombocytopenic purpura, as they require more time to review the application.

Cramer's 'Mad Money' Recap: June 20 (TheStreet.com)
Cramer likes this components maker as part of his 'new tech' theme.

Synapse Biomedical Receives FDA Approval Of NeuRx Diaphragm Pacing System (DPS)(TM) For Spinal Cord Injury Breathing ... (Medical News Today)
Synapse Biomedical Inc. (http://www.synapsebiomedical.com) announced it has received approval from the U.S. Food and Drug Administration (FDA) for its NeuRx DPS(TM) for ventilator-dependent Spinal Cord Injury (SCI) patients who lack voluntary control of their diaphragms. With the FDA's approval, SCI patients and their caregivers throughout the U.S.